10x Genomics - Class A opened lower at $73.65, compared with its previous close of $81.55. In the last trading session, the stock traded between $68.31 and $75.79. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in 10x Genomics - Class A is now worth
$ 42.62
resulting in a loss of
$ 57.38 (57.38%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 15 Analysts
Buy
40%
Hold
60%
Sell
0%
Markets Today
Today's Change
$-12.81 (-15.71%)
Day High
$75.79
Day Low
$68.31
Day Open
$73.65
Prev Close
$81.55
Volume
26,04,270
1W Return
-1.45%
1M Return
-23.66%
3M Return
48.54%
6M Return
240.30%
1Y Return
432.88%
Fundamentals
Market Cap ($ Mn)
8,263
PE Ratio
-
PB Ratio
9.71
PEG Ratio
-
ROE
-5.77%
ROCE
-7.08%
EPS (TTM)
$-0.14
Investment Returns
1 Week
-1.45%
1 Month
-23.66%
3 Months
48.54%
6 Months
240.30%
9 Months
230.49%
Financials
Quarterly
All values in $ Mn
165.0
Dec 24
154.9
Mar 25
172.9
Jun 25
149.0
Sep 25
166.0
Dec 25
151.0
Jun 26
Updates
12Oct
Canaccord Genuity raises 10x Genomics price target to $100
Canaccord Genuity analyst Kyle Mikson maintained a Buy rating on 10x Genomics. Price target raised from $60 to $100. The revision represents a $40 increase in the price target.
Piper Sandler raised the price target for 10x Genomics to $80. The previous price target stood at $47. The firm maintained a Neutral rating on the stock.
1mo ago
31Aug
10x Genomics wins patent verdict against Qiagen unit Parse
A US jury found Qiagen unit Parse Biosciences willfully infringed 10x Genomics patents. The verdict awards 10x Genomics over $4.8 million in damages based on a 14% royalty rate. 10x plans to seek enhanced damages, attorney fees, and a permanent injunction. Analysts view the verdict as a win for 10x, though Qiagen faces immaterial financial impact. This follows a separate May 2025 patent settlement with Bruker Corporation worth $68 million.
1mo ago
17Jul
Leerink raises 10x Genomics price target to $40
Leerink Partners analyst Mike Kratky maintained 10x Genomics with a Market Perform rating and raised the price target to $40 from $23.
3mo ago
16Jul
10x Genomics to report Q2 2026 results on August 6
10x Genomics, Inc. announced it will report financial results for the quarter ended June 30, 2026, on August 6, 2026, after market close. A conference call is scheduled for 1:30 p.m. PT to discuss results and outlook. The webcast will be archived for 45 days.
3mo ago
10Jul
Morgan Stanley maintains Equal-Weight on 10x Genomics, raises target to $37
Morgan Stanley analyst Tejas Savant maintained an Equal-Weight rating on 10x Genomics (NASDAQ: TXG) while raising the price target to $37 from the previous $22. The adjustment signals a revised outlook on valuation, though the stock's risk-reward profile is viewed as balanced.
